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This review summarizes the development of gene editing from early proof-of-concept studies in the 1980’s 
to contemporary programmable and RNA-guided nucleases which enable rapid and precise alteration of 
DNA sequences of almost any living cell. With an average of one CRISPR Cas9 paper published every four 
hours in 2017, this review cannot highlight all new developments, but a number of key improvements 
including increases in efficiency, a range of new options to reduce off-target effects and plans for CRISPR to 




Genome editing enables precise changes to be made in the genome of living cells. The technique was 
originally developed in the 1980’s but largely limited to use in mice. The discovery that a targeted double 
stranded break (DSB) at a unique site in the genome, close to the site to be changed, could substantially 
increase the efficiency of editing  raised the possibility of using the technique in a broader range of animal 
models and potentially human cells. But the challenge was to identify reagents that could create targeted 
breaks at a unique genomic location with minimal off-target effects. In 2005, the demonstration that 
programmable zinc finger nucleases (ZFNs) could perform this task, led to a number of proof-of-concept 
studies, but a limitation was the ease with which effective ZFNs could be produced. In 2009, the 
development of TAL-effector nucleases (TALENs) increased the specificity of gene editing and the ease of 
design and production. However, it wasn’t until  2013 and the development of the CRISPR Cas9/guideRNA 
that gene editing became a research tool that any lab could use.  
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Genome editing is a technique that enables precise changes to be made in the genome of a living cell. It can 
be performed in ex vivo culture and selection applied to enrich for edited cells. It can also be performed 
ante natal in essentially any animal species, and has been used to edit single cell embryos, which when 
implanted into surrogate mothers, develop into adults in which all cells are edited. Early forms of this 
technique revolutionised the understanding of murine physiology in the 1980’s, but limitations in the 
technology restricted its application to human cells and therapeutic development.  
 
At the dawn of the new millennium, many of these limitations have been resolved and a broad range of 
gene editing tools are available to precisely target unique sites in the genome. It is now possible to 
precisely, efficiently and permanently edit the genome of cells from virtually any organism on the planet in 
order to study complex physiological processes and genetic disorders. Gene editing has been used to 
establish proof-of-concept as a treatment of such genetic disorders in these model systems, and in 
December 2017, Brian Madeau, a 44-year old with Hunter syndrome became the first person to reveive 
gene editing technology in a phase I/II clinical trials. Moreover, gene-edited cells have already been used 
successfully in a small number of therapeutic studies in human, and as discussed below, one type of edited 
cells has recently been approved by the FDA as a licenced medicine. 
 
The purpose of this review is to introduce the basic techniques used to edit (see Box 1) the genome of living 
cells in the context of three major biomedical applications: 
• Establishing how particular DNA sequences control the normal physiology of individual cells in ex vivo 
culture. 
• Exploring how certain mutations in the DNA sequence, either acquired or inherited, can cause more 
than 100 different types of cancer and over 7,000 genetic disorders.  
• Development as the basis for a potential treatment for many of these diseases, such as cystic fibrosis 
(CF), sickle-cell anaemia (SCA) and B-cell Acute Lymphoblastic Leukaemia/Lymphoma (B-ALL). 
 
INSERT BOX 1 
 
DNA structure, replication and repair 
 
To fully understand editing, we need to understand some of the key features of the structure of DNA, and 
the mechanisms by which it is replicated and repaired in cells. DNA is made from just four nucleotides (or 
bases), abbreviated A, C, G and T, arranged as two antiparallel strands in a double helical configuration 
(Figure 1a). The two strands are held together by hydrogen bonds between the nucleotides which always 
occur as either an A-T base-pair, or G-C base-pair.  As noted by Watson and Crick in their 1953 paper on the 
structure of DNA, this specific base pairing “immediately suggests a possible copying mechanism for the 
genetic material”. If it’s not immediately obvious, the point they were making is that the anti-parallel 
arrangement of DNA nucleotides means that if the strands of DNA are pulled apart (unwound), then the 
two individual strands have all the information necessary to make two new double stranded DNA 
molecules, provided the two strands are surrounded by the four DNA bases in the trinucleotide form with 
the appropriate enzymes and cellular environment. Suitable environments range from the nucleus of a 
mammalian cell to the isolated components in a polymerase chain reaction (PCR) in a test tube. 
 
This understanding of DNA replication underpins an understanding of DNA repair mechanisms, which is the 
basis for all DNA editing. When the strands separate (Figure 1b), short “primer” molecules bind in a base-
pair specific manner (Figure 1c) and initiate DNA synthesis in a 5’ to 3’ direction. In the upper strand in the 
diagram, the template strand is undamaged and DNA synthesis continues in an uninterrupted manner 
(Figure 1d). However, the lower strand in this diagram has been damaged such that the phosphodiester 
linkage between two of the bases has been broken (Figure 1e) and DNA synthesis cannot cross what is 
effectively a double-stranded break (DSB). Such DSBs occur routinely during DNA replication but cells have 
evolved with DNA repair enzymes that are expressed during the synthesis (S) phase of the cell cycle which 
can repair these DSBs by a process known as homology directed repair (HDR). Repair is initiated by 
enzymes which recognise the DSB then resect some of the DNA (~300 bases) to expose DNA sequences 
with free 3’ ends. These 3’ ends can invade and bind to the newly synthesised sister chromatid in a base-
pair specific manner (Figure 1f), and use it as a template for DNA synthesis which then continues across the 
DSB (Figure 1g). Once the DSB has been crossed, the strands reanneal to the distal side of the DSB and 
synthesise new DNA to fill in the gaps and complete the HDR process (Figure 1h).  As shown below, the HDR 
repair pathway is key to most precision gene editing strategies. However, it is worth noting that HDR is not 
the default repair for a DSB, with the most likely outcome for repair of a DSB being non-homologous end 
joining (NHEJ). This typically results in the joining of the two free ends of DNA with the creation of small 
insertions of deletions (indels) following repair. Whilst the formation of these indels can be mutagenic, in 
that gene sequences are altered, the re-joining of the DNA rescues the chromosome and thus enables the 
cell to replicate. The consequences of NHEJ for precision gene editing strategies are discussed below.  
 
INSERT FIGURE 1 
 
Editing and Genetic Disorders 
 
The concept of genetic disease or inborn metabolic disorders was defined by Archibald Garrod in 1902, but 
it was another 55 years before Vernon Ingram confirmed that changes in the DNA sequence gave rise to 
changes in a protein sequence (Ingram, 1957). This work which identified the single nucleotide change in 
the beta-globin gene (an A replaced by a T) accounted for the replacement of the amino acid glutamine at 
the sixth position of the haemoglobin B chain with a valine which in turn gives rise to sickle cell anaemia 
when both copies of the gene carry this mutation which affects millions of people worldwide. 
 
The importance of this finding should not be underestimated as it not only confirmed the hypothesis that a 
substitution in the DNA leads to a substitution in the amino acid sequence of a protein, but it also under-
pinned efforts of Holley, Khorana and Nirenberg to successfully crack the genetic code and win the Nobel 
Prize in Physiology or Medicine in 1968 (www.nobelprize.org/nobel_prizes/medicine/laureates/1968), and 
the concept of the central dogma of molecular biology. Together, these findings led to the realisation that if 
techniques could be developed to manipulate DNA sequences in living cells, this would significantly 
increase our ability to understand the physiological process of that cell. And if that cell was an embryonic 
stem (ES) cell, then this gives rise to the possibility of studying the effects of manipulated DNA sequences in 
whole animals derived from that cell.  
 
Of Mice but not Men 
 
Over the next 20 years, the advances in molecular genetics and development of recombinant DNA 
technology culminated in the development of a gene editing strategy (then known as gene targeting) that 
enabled precise changes to be made in mouse ES cells. The technique relied upon the generation of long 
DNA molecules (≥10kb) known as targeting constructs that could be microinjected into ES cells. These 
constructs contained long homology arms (DNA sequences that precisely matched the DNA sequence of 
the target gene) flanking the desired DNA sequence to be introduced, as well as positive and negative 
selection markers. The positive selection allowed the identification (and selection) of cells that had been 
modified (precisely or randomly), and the negative selection allowed the subsequent identification (and 
removal) of cells that underwent random targeting. The end result is a small population of precisely 
targeted (edited) ES cells. The parallel development of protocols to generate mice from ES cells enabled the 
generation of the first gene edited animal in 1982. This strategy revolutionised the study of mouse 
physiology and in vivo modelling of genetic and physiological disorders, culminating in the 2007 Nobel Prize 
in Medicine or Physiology (www.nobelprize.org/nobel_prizes/medicine/laureates/2007).  
 
The technique was largely restricted to engineering of mouse ES cells due to the low efficiency and 
consequent need for strong selection strategies as described above, even though the key to significantly 
improving the efficiency, a double-stranded break close to the region to be edited, was identified in 1984. 
Oliver Smithies and colleagues established a two-plasmid system to test the idea using restriction enzymes. 
One of the plasmids contained a reporter gene with a small deletion such that it lost its function, the 
second contain the same gene with a different deletion which also led to loss of function. When they 
transfected either plasmid individually into cells, they saw no reporter activity. However, when co-
transfected, they detected a low incidence of recombination events where one plasmid acted as a donor to 
repair the other by HDR. If they made a targeted DSB in one of the plasmids before they did the co-
transfection, they doubled the efficiency of HDR. However, if the DSB was made very close to the target 
site, the efficiency of HDR increased by 22-fold (Kucherlapati et al., 1984).  But why wasn’t this approach 
pursued for editing genomes? 
 
Breaking up is hard to do; do the maths!  
 
With apologies to Neil Sedaka, creating a unique double-stranded break in genomic DNA isn’t that easy. 
The reason is simply that unique sequences in DNA must be at least 16 bases long, and until the turn of the 
21st century reagents to specifically recognises and cut such a long sequence weren’t available (see box 2).  
 
INSERT BOX 2 
 
Programmable Zinc Finger Nucleases – the breakthrough moment for Gene Editing 
 
Zinc finger nucleases are synthetic enzymes comprising three (or more) zinc finger domains, each of which 
binds three bp of DNA, linked together to create an artificial DNA binding protein binding ≥9 bp of DNA. In 
order to cut DNA, the zinc finger domains are fused to one half of the FokI nuclease domain such that when 
two ZFNs bind the two unique 9 bp sites, separated by a suitable spacer, they can cut within the spacer to 
make a double stranded break. The original creator of this approach used naturally occurring ZF domains 
assembled to recognise a unique sequence in the DNA genome of the E. coli bacteriophage lambda. 
Subsequent studies by academic and industry groups led to the identification of a set of rules to allow ZFNs 
to be designed to target essentially any target site in the human genome culminating in precision repair of 
mutations in the IL-2 receptor g chain gene by HDR in ~20% of transfected cells (Urnov et al., 2005). This 
breakthrough quickly led to a number of pivotal proof-of-concept experiments in gene editing including: 
• ability to make gene targeted animals by editing in vitro fertilised embryos rather than ES cells (Guerts 
et al., 2009); prior to this, editing cells from animals other than mice was very time consuming due to 
lack of ES cell lines. This approach of ex vivo editing has been developed in subsequent years to model 
human disease and study physiological processes in rodents (Birling et al. 2017) and many other species 
(Whitelaw et al., 2016; Morales and Wingert, 2017). 
• ability to edit in vivo, correcting multiple mutations at once, and restoring normal physiological 
function in a disease model (Li et al., 2011); a truly revolutionary study showing the power of gene 
editing to permanently correct a defect in a mouse model haemophilia B. Moreover, by using a 
"superexon" (or partial cDNA) as donor, this approach can potentially correct many different disease-
causing mutations in the same gene, which is potentially critical for the widespread clinical 
development of gene editing. Indeed, the first direct in vivo use of ZFNs in humans involved a cDNA 
integration strategy (Sangamo, 2017)  
 
Gene Edited Cells for Clinical Application 
 
A few years after the development of ZFNs, a second gene editing system was reported, the Tal-effector 
nucleases (TALENs). These reagents have been used by many labs and are now easy to assemble and use 
for numerous applications. One of the most exciting developments has been use in the development of 
genetically engineered T-cells which express a chimeric antigen receptor (CAR) which recognises a specific 
antigen on cancer cells in B-cell Acute Lymphoblastic Leukaemia. The CAR was added to the T cells by 
conventional genetic engineering approaches, but two additional genetic changes to the T cells to increase 
the safety and efficacy where introduced by TALEN gene editing. The use of CAR-T cells to treat B-ALL was  
approved by the US FDA on 30th August 2017 
(www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm). 
 
The CRISPR Rising: where were you on 17th August 2012? 
 
In spite of the enormous potential applications for both ZFNs and TALENs, the prospect of designing and 
synthesising these recombinant nucleases to target a gene of interest limited the widespread uptake of 
these reagents; the field was on the lookout for a simpler way to make a unique cut in the genome of a 
living cell. Whilst maybe not (yet) as memorable as 20th July 1969 (first human on the moon), 9th November 
1989 (fall of the Berlin wall), or 5th July 1996 (birth of Dolly the sheep), 28th June 2012 marked the online 
publication that the clustered regularly interspaced short palindromic repeat (CRISPR) sequences in the 
genome of Streptococcus pyogenes encoded a dual-RNA structure (tracrRNA and crRNA) that directs a Cas9 
endonuclease to make targeted DSBs in DNA, and that this “could offer considerable potential for gene-
targeting and genome-editing applications” (Jinek et al., 2012). Subsequent studies described modifications 
to Cas9 such as codon-optimised to maximise expression in mammalian cells, and addition of a nuclear 
localisation signal to facilitate Cas9 entry into the nucleus. Many studies also utilised a single guide RNA 
(sgRNA, often abbreviated further to gRNA) of ~120 bases (Figure 2A), which is essentially a fusion of the 
tracrRNA and crRNA molecules.  
 
Once expressed in or introduced to the mammalian cell, the Cas9/gRNA complex migrates to the nucleus 
and scans the genome for a short DNA triplet sequence (normally 5’-NGG-3’) known as a PAM. When the 
Cas9/gRNA binds to a PAM, it then partially unwinds the DNA upstream of the PAM; if the target region of 
the gRNA can bind with a 20:20 match, the Cas9 nuclease then cuts both strands of DNA 3 bp upstream of 
the PAM (Sternberg et al., 2014). As predicted above, once Cas9/gRNA has made a unique DSB, then the 
same DNA repair pathways exploited by ZFNs and TALENs can be used for editing. 
 
INSERT FIGURE 2 
 
Design, Cloning, Testing, Selection and Off-Target 
 
This section gives a brief overview of how to get started with CRISPR in the lab, with more detailed 
information available in protocol and methodology papers (Ran et al., 2013; Byrne et al., 2014; Wang G et 
al., 2017).  
 
gRNA target selection – there are numerous freely available online tools which in essence follow three 
basic rules. First, they identify a PAM sequence in your target gene. Second, they identify the 20-nucleotide 
target sequence upstream of the PAM. Third, they scan the genome of the species you are intending to edit 
and assess for potential off-target sequences, that is sequences that occur elsewhere in the genome which 
match or nearly match your target. Some programmes will also generate the two oligo sequences you need 
to synthesise to clone into the Cas9/gRNA dual expression vector (see Figure 2B). See Lee et al., 2017 for a 
review of different gRNA design tools. 
 
Cloning gRNAs –  a number of plasmid-based systems are available to co-express Cas9 and a specific gRNA. 
Once a gRNA target has been identified, the target sequence can be made as a double-stranded fragment 
of DNA by annealing two short oligonucleotides and using Golden Gate cloning to insert them into a dual 
gRNA/NLS-Cas9 expression vector. Golden Gate cloning is possibly one of the simplest cloning techniques 
since all the reagents are added to the same tube then subjected to 10 cycles of 37˚C/16˚C over a 2-3 hr 
period then transformed into E. coli. Typically, ≥80% of the clones isolated the following day contain the 
correct gRNA cloned in the correct orientation (Ran et al., 2017).  
 
Avoiding cloning altogether – to simplify matters further, cloning can be completely avoided by using 
recombinant Cas9 protein mixed with in vitro transcribed gRNA molecules (Lingeman et al,. 2017), or 
chemically modified gRNA which can improve stability and enhance editing efficiency (Hendel et al., 2015). 
Alternatively, an RNA only approach is possible using the mRNA which encodes Cas9 co-transfected with 
the gRNA molecule (Wang HX et al., 2017). 
 
Testing gRNAs – if a gRNA is successful at creating a DSB, the cells will normally repair this by NHEJ which 
usually creates small insertions or deletions (indels; Hollywood et al., 2016). As the indels are usually small 
(≤25 bp) they are not that easy to detect by conventional PCR. However, if PCR is performed and the final 
reaction is heated to 95˚C and allow to cool slowly, a significant proportion of heteroduplex molecules 
should form and these can easily be detected using nuclease which can cut these heteroduplex regions (see 
Lee et al., 2012). Alternatively, pairs of gRNAs can be tested simultaneously to generate deletions of 
defined size which can be readily detected by conventional PCR (see Sanz et al., 2017).  
 
Donor Design – as shown in Figure 3 below, the donor molecule is key to introducing the correct sequence 
once a targeted DSB has been made. The donor can be a single stranded oligonucleotide (c. 100 bases) or a 
much longer double-stranded DNA molecule usually in the form of a plasmid (Byrne et al., 2014). In both 
cases, the donor should have homology arms (HAleft and HAright in Figure 3), extended regions of sequence 
identity either side of the region to be edited. The donor should obviously contain the desired nucleotide 
changes required to introduce or correct mutations in the genome, and it is also possible to make changes 
in the donor such that the PAM is removed from the genome to prevent subsequent cutting once the 
desired change in the genome has been made (see Figure 3).  
 
Reducing off-target effects – one of the early challenges with Cas9/gRNA editing was the relatively high 
level of off-target effects as discussed in Fu et al., 2013. An off-target effect occurs when Cas9/gRNA 
creates a DSB at a location within the genome which has a very similar sequences to the original 23 base-
pair target site. Such DSBs are typically repaired by the NHEJ pathway which usually results in indel 
formation at the off-target site which can then have undesired consequences on gene expression and/or 
function. Numerous options have been devised to prevent off-target effects, possibly the simplest is to 
make gRNAs 1-2 bases shorter at the 5’ end; this can significantly reduce DSB formation at off-target sites 
whilst retaining sufficient activity at the correct target site (Fu et al., 2014). The use of Cas9/gRNA protein-
RNA particles (Kim 2014), and/or Cas9 variants such as Hypa-Cas9 (Chen et al., 2017) have been shown to 
reduce off-target effects with very little impact on on-target activity,  
 
Selection of edited cells – making precise alterations in the genome of cells is now relatively easy, but the 
isolation and selection of those isn’t necessarily as simple. Numerous protocols have been devised using 
selection markers which can be subsequently removed (Wang et al., 2017) or PCR-based enrichment 
strategies to avoid the need for selectable markers (Suzuki et al., 2016).  
 
Precision repair of cystic fibrosis-causing mutations by HDR 
 
One of the major goals of our research is to apply gene editing techniques to better understand and 
potentially treat Cystic Fibrosis, which is caused by mutations in the CFTR gene (Rommens et al., 1989; 
Riordan et al., 1989; Kerem et al., 1989). To date, ZFNs, TALENs and Cas9/gRNA have all been used to edit 
CF-causing mutations in a range of cell types using NHEJ and HDR methods (Harrison et al., 2016; Alton et 
al., 2016; Sanz et al., 2017; Hart and Harrison, 2017). An overview of the mechanism by which Cas9/gRNA 
HDR is could be used to repair a stop codon mutation in the CFTR gene is shown in Figure 3. 
 




Gene editing is a long-established technique dating back ~30 years BC (before CRISPR), but for much of this 
time was limited mainly to mouse ES cells and specialised research groups. The development of ZFNs and 
TALENs set the scene for a revolution, but it took the advent Cas9/gRNA to make gene editing truly 
accessible to any research laboratory.  
 
It took less than 50 years from the discovery of structure and function of DNA (Watson and Crick, 1953) to 
the first draft of the human genome sequence (Lander et al., 2001). The impact of these discoveries has 
already revolutionised our understanding of cell and organismal physiology, and genetic disease and cancer.  
 
It is only year 6 CE (CRISPR Era), but already Genome-Read projects such as 100,000 genomes look set to be 
eclipsed by Genome-Write projects, and the unstoppable growth in Cas9 editing technology and 
applications (Figure 4) will undoubtedly play a guiding role. Further advances in technology to re-write the 
genome should be paralleled by a commitment to both scientific and public discussion on the ethical and 
regulatory issues surrounding how these techniques will be used (Boeke et al., 2016; Ormond et al., 2017; 
Parry, 2017, Harrison et al., 2017), and where we might be by 50 CE? 
 





Figure and Box Legends 
 
 
Box 1: How do you precisely edit a DNA sequence, in a live cell? 
Editing a DNA sequence is somewhat similar to editing a text document on a computer.   
Step 1 is to find (ctrl F) the precise DNA sequence to be changed then to cut it out (ctrl X). With CRISPR 
gene editing, a guide RNA molecule in combination with the Cas9 nuclease is used to find the unique target 
sequence in the genome and cut the DNA at that point. 
Step 2 in text editing is to copy (ctrl C) a few letters or a word from a dictionary and paste (ctrl V) them into 
the correct place to change the meaning of a sentence (and potential the overall outcome of the 
document). In cells, we don’t use a dictionary, rather a synthetic piece of DNA with the desired sequence is 
inserted into the target cells. The synthetic DNA contains the new DNA sequences as well as some 
sequence similarity (or homology) to the target region of the selected gene which helps it to be correctly 
copied and pasted (or ligated) into the cut site generated by Cas9/guide RNA. The end result is genomic 
DNA with a sequence corresponding to that in the synthetic DNA (and potential alterations to the cell’s 
physiology). In summary, the Cas9/guide RNA makes a targeted break in the genome, and the synthetic 
DNA provides the new information. The process is mediated in cells by a naturally occurring DNA repair 
mechanisms known as homology-directed repair (HDR). 
 
 
Figure 1: Overview of DNA replication and repair of double stranded breaks (DSBs); see text for details. 
 
 
Box 2: Genomic Maths 
DNA has four bases (A, C, G and T), so a 6 base sequence such as GAATTC should occur, on average every 46 
= 4,096 bases of a random DNA sequence. Enzymes such as the EcoRI endonuclease can recognise and cut 
such 6 base sequences, which is fine if you are working with plasmids (typically ~5,000 bp). However, for 
the human genome, 3x109 bp, such enzymes would cut ≥750,000 times! 
 
The mathematics is simple: 416 = 4.3 x 109, showing that a unique site should occur if the DNA nuclease 
recognises at least 16 bases. As shown below, the three most common editing nucleases have recognition 
sequences in excess of this number - ZFNs recognise 18-24 bp, Cas9/gRNA recognises 19-20 bp and TALENs 
recognise ≥24 bp. 
 
 
Figure 2: Cas9/gRNA. A) Cartoon representation of Cas9/gRNA showing PAM site, target sequence and cut 
site (red triangles). B) DNA insert encoding target sequence to insert into dual gRNA/ NLS-Cas9 expression 
vector using Golden Gate cloning. 
 
 
Figure 3: CRISPR Cas9/gRNA HDR to correct W1282X mutation in CFTR gene.  
 
Six key stages are shown in the diagram, using an alternative set of words based on the CRISPR acronym (Jansen et al. 
2002); note that Figure 5 is shown in the same format as Figure 1 which explained the HDR repair mechanism. The 
upper sequence (blue) represents the donor, the lower sequence (black) is the genome with amino acid sequence 
(three letter code) shown above the DNA sequence and * is the stop codon. Bars either side represent extended 
stretches of DNA (typically 500-1000 bp for donor, or remainder of chromosome arms for genome) 
 
Cut  Cas9/gRNA makes a DSB 3 bp upstream of the PAM site 
Resect  Cellular exonucleases resect the free 5’ ends of DNA exposing 3’ ends. 
Invade  A free 3’ end invades donor and binds in a sequence specific manner…  
Synthesis … which triggers DNA synthesis in 5’-3’ direction copying the donor sequence  
Proof-read Mismatches are corrected by removing part of one strand … 
Repair … then the gap is filled in. The TGA codon is edited to TGG  
 
Note the donor is deliberately modified in this example to edit the PAM sequence in the genome to prevent recutting 
by Cas9/gRNA whilst preserving the same amino acid coding capacity. 
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